Supplementary MaterialsAdditional file 1: Calibration curve: progression-free and overall survival. perspectives of the United States (US), United Kingdom (UK), and China. Sensitivity analyses were performed to test the uncertainties of the results. Quality-adjusted life-years (QALYs) and incremental cost-effectiveness ratios (ICERs) were used. Results Nivolumab plus ipilimumab gained 0.70C0.76 QALYs compared with sunitinib. Our analysis determined… Continue reading Supplementary MaterialsAdditional file 1: Calibration curve: progression-free and overall survival. perspectives